SKN | Barclays Reaffirms Confidence in McKesson Despite Lower Price Target

Key Takeaways

• Barclays maintained its Overweight rating on McKesson while reducing its price target from $1,050 to $925.
• The revised target reflects increased caution around regulatory and market uncertainties, including the Inflation Reduction Act, biosimilars, and GLP-1 therapies.
• McKesson recently completed a $1.25 billion investment transaction with Apollo that values its Medical-Surgical Solutions business at approximately $13 billion.
• The continued support from major investment banks suggests confidence in McKesson’s long-term business model despite near-term industry challenges.

Why Barclays Remains Positive on McKesson

Barclays continues to view McKesson as one of the stronger companies within the healthcare distribution sector, even after lowering its price target. The firm’s decision to maintain an Overweight rating indicates that analysts still see attractive long-term value despite increasing uncertainty across several healthcare market segments.

The revised target reflects a more conservative outlook rather than a deterioration in McKesson’s core business. Barclays cited limited visibility surrounding the Inflation Reduction Act, expanding biosimilar competition, and the growing impact of GLP-1 medications as factors that could influence future earnings dynamics.

For investors, the key takeaway is that Barclays is adjusting expectations to reflect evolving industry conditions while maintaining confidence in McKesson’s ability to navigate those challenges.

Apollo Transaction Highlights Asset Value

A significant recent development for McKesson was the completion of a strategic investment from funds managed by affiliates of Apollo.

The transaction involved a $1.25 billion investment in McKesson’s Medical-Surgical Solutions (MMS) business through convertible preferred equity. The deal values the MMS division at approximately $13 billion while allowing McKesson to retain majority ownership and operational control.

For shareholders, this transaction provides an external validation of the underlying value within one of McKesson’s key business segments. It also unlocks capital while preserving strategic flexibility, allowing the company to continue benefiting from future growth opportunities within the medical-surgical market.

Such transactions can often strengthen balance sheet flexibility and create additional options for future capital allocation initiatives.

Healthcare Distribution Faces Industry Changes

The healthcare distribution sector is entering a period of transformation driven by policy changes, evolving pharmaceutical markets, and new treatment categories.

The Inflation Reduction Act continues to reshape drug pricing discussions, while biosimilar products are increasing competitive pressure across several therapeutic areas. Meanwhile, the rapid adoption of GLP-1 treatments is influencing healthcare spending patterns and creating new questions about future pharmaceutical demand.

Despite these developments, McKesson maintains advantages through its scale, distribution network, customer relationships, and diversified healthcare services platform.

These strengths help position the company to adapt as healthcare markets continue to evolve.

What Investors Should Watch Going Forward

While Barclays has become incrementally more conservative in its forecasts, the broader investment case for McKesson remains tied to operational execution, healthcare demand trends, and the company’s ability to maintain its leadership position within pharmaceutical distribution.

Recent support from both Barclays and UBS demonstrates that major institutions continue to see value in the company despite a more complex operating environment.

Investors will likely focus on future earnings guidance, regulatory developments, pharmaceutical market trends, and the performance of the Medical-Surgical Solutions business as important indicators of long-term growth potential.

Closing Insights

McKesson’s latest developments highlight a company balancing industry change with strategic execution. Barclays’ continued Overweight rating, combined with Apollo’s investment in the Medical-Surgical Solutions business, suggests that market participants continue to recognize the strength of McKesson’s core franchise. While regulatory shifts and evolving healthcare trends introduce uncertainty, the company remains positioned to leverage its scale, operational reach, and strategic assets to support long-term shareholder value.

For a confidential discussion with SKN Advisory regarding healthcare investment trends, pharmaceutical distribution markets, healthcare infrastructure opportunities, strategic capital allocation, or long-term sector positioning, contact our senior advisory team.